Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints—a prospective observational study

Institute of Complementary Medicine, University Hospital, Zurich, Switzerland.
Gynecological Endocrinology (Impact Factor: 1.33). 10/2011; 27(10):844-8. DOI: 10.3109/09513590.2010.538097
Source: PubMed

ABSTRACT The antihormonal therapy of breast cancer patients with the antiestrogen tamoxifen often induces or aggravates menopausal complaints. As estrogen substitution is contraindicated, herbal alternatives, e.g. extracts of black cohosh are often used.
A prospective observational study was carried out in 50 breast cancer patients with tamoxifen treatment. All patients had had surgery, most of them had undergone radiation therapy (87%) and approximately 50% had received chemotherapy. Every patient was treated with an isopropanolic extract of black cohosh (1-4 tablets, 2.5 mg) for 6 months. Patients recorded their complaints before therapy and after 1, 3, and 6 months of therapy using the menopause rating scale (MRS II).
The reduction of the total MRS II score under black cohosh treatment from 17.6 to 13.6 was statistically significant. Hot flashes, sweating, sleep problems, and anxiety improved, whereas urogenital and musculoskeletal complaints did not change. In all, 22 patients reported adverse events, none of which were linked with the study medication; 90% reported the tolerability of the black cohosh extract as very good or good.
Black cohosh extract seems to be a reasonable treatment approach in tamoxifen treated breast cancer patients with predominantly psychovegetative symptoms.

43 Reads
  • Source
    • "); (Saadati et al. 2013) #3447 (Agarwal et al. 2014; Pinkerton et al. 2014); SSRIs: (Simon et al. 2013; Aedo et al. 2011; Suvanto-Luukkonen et al. 2005; Oktem et al. 2007), venlafaxine (Evans et al. 2005; Boekhout et al. 2011; Vitolins et al. 2013), desvenlafaxine (Speroff et al. 2008; Archer et al. 2009a; Archer et al. 2009b; Cheng et al. 2013; Bouchard et al. 2012; Pinkerton et al. 2013), isoflavones (Albertazzi et al. 1998; Han et al. 2002; van de Weijer & Barentsen 2002; Jeri 2002; Sammartino et al. 2003; Nahas et al. 2004; Nahas et al. 2007; Khaodhiar et al. 2008; Cheng et al. 2007; Radhakrishnan et al. 2009; Ye et al. 2012; Aso et al. 2012; Mainini et al. 2013; D'Anna et al. 2007; D'Anna et al. 2009; Ferrari 2009; Evans et al. 2011; Murkies et al. 1995; Crisafulli et al. 2004; Labos et al. 2013; Upmalis et al. 2000; Faure et al. 2002); hops (Heyerick et al. 2006); red clover (Hidalgo et al. 2005; Lipovac et al. 2012), flaxseed (Colli et al. 2012), St. John's wort (Uebelhack et al. 2006; Briese et al. 2007), French maritime pine bark (Yang et al. 2007; Kohama & Negami 2013), Sibiric Rhubarb (Heger et al. 2006; Kaszkin-Bettag et al. 2007; Kaszkin-Bettag et al. 2009; Hasper et al. 2009), and CREs (Drewe et al. 2013; Lopatka et al. 2007; Vermes et al. 2005; Liske et al. 2002; Frei-Kleiner et al. 2005; Schellenberg et al. 2012; Osmers et al. 2005; Ross 2012; Newton et al. 2006; Geller et al. 2009; Stoll 1987; Wuttke et al. 2003; Nappi et al. 2005; Bai et al. 2007; Uebelhack et al. 2006; Briese et al. 2007; Oktem et al. 2007; Hernández Munoz & Pluchino 2003; Rostock et al. 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated. This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation. A PubMed search included literature up to June 19, 2014 without limits for initial dates or language, with the search terms, (hot flush* OR hot flash*) AND (clinical trial* OR clinical stud*) AND (randomi* OR observational) NOT review). Retrieved references identified further papers. The focus was on hot flushes; other symptoms (night sweats, irritability, etc.) were not specifically screened. Included were some 610 clinical studies where a measured effect of the intervention, intensity and severity were documented, and where patients received treatment of pharmaceutical quality. Only 147 of these references described studies with alternative non-hormonal treatments in post-menopausal women and in breast and prostate cancer survivors; these results are presented in Additional file 1. The most effective hot flush treatment is oestrogenic hormones, or a combination of oestrogen and progestins, though benefits are partially outweighed by a significantly increased risk for breast cancer development. This review illustrates that certain non-hormonal treatments, including selective serotonin reuptake inhibitors, gabapentin/pregabalin, and Cimicifuga racemosa extracts, show a positive risk-benefit ratio. Key pointsSeveral non-hormonal alternatives to hormonal therapy have been established and registered for the treatment of vasomotor climacteric symptoms in peri- and post-menopausal women.There are indications that non-hormonal treatments are useful alternatives in patients with a history of breast and prostate cancer. However, confirmation by larger clinical trials is required.
    SpringerPlus 12/2015; 4(1). DOI:10.1186/s40064-015-0808-y
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study sought to confirm the efficacy and safety of the currently recognized dose of Cimicifugae racemosae rhizoma (40 mg/day) and to evaluate a higher dose and its associated physiological effects. We conducted a controlled, randomized, double-blinded parallel group study of perimenopausal and postmenopausal women treated with two different doses (39 mg and 127.3 mg) of a unique C. racemosa preparation over a 24-week period. Efficacy and tolerability were determined by the Kupperman Menopause Index, Self-Rating Depression Scale (SDS), a global assessment of tolerability, adverse events, routine hematology, and biochemical tests. To determine if the unique C. racemosa preparation exerts its effect through an estrogen-identical mode of action, we investigated vaginal cytology and gynecologically relevant hormones. Both perimenopausal and postmenopausal patients tolerated the treatment well, and menopausal symptoms decreased regardless of dose (responder rate 70% and 72%, respectively). The lack of change in vaginal cytology measures indicates a nonestrogenic effect of the tested extract in this critical organ. Likewise, the lack of significant changes in the levels of gynecologically relevant hormones does not indicate an overall estrogenic effect. The higher dose did not exert a significantly greater effect on any end point. Thus, the currently recognized standard dose of the isopropanolic aqueous C. racemosa extract should be preferred over the higher dose. Despite the absence of a placebo group, this study suggests that C. racemosa extract is associated with improvement in menopause symptoms without evidence of estrogenlike effects.
    Journal of Women s Health &amp Gender-Based Medicine 04/2002; 11(2):163-74. DOI:10.1089/152460902753645308
  • [Show abstract] [Hide abstract]
    ABSTRACT: Viele Brustkrebspatientinnen leiden unter den Nebenwirkungen ihrer antihormonellen Therapie. Klimakterische Beschwerden in Form von Hitzewallungen, Nachtschweiß, Libidoverlust, Ängsten, Depressionen oder auch Muskel- und Gelenkschmerzen führen in vielen Fällen zu einer Verschlechterung der Therapieadhärenz. Die Effektivität einer Begleittherapie mit selektiven Serotonin-Wiederaufnahmehemmern (SSRI), Gabapentin oder Clonidin konnte in verschiedenen randomisierten klinischen Studien (RCT) belegt werden. Allerdings lehnen viele Patientinnen eine Behandlung mit diesen Medikamenten ab, u. a. weil sie zusätzliche Nebenwirkungen fürchten. Demgegenüber besteht eine große Nachfrage nach komplementären Therapiemöglichkeiten, aber erst in den letzten Jahren gibt es zunehmend mehr und auch qualitativ bessere klinische Studien zu ihrer wissenschaftlichen Erforschung. Drei RCT mit isolierten Soja-Isoflavonen zeigten keine Überlegenheit gegenüber Placebo. Drei von fünf klinischen Studien mit Extrakt aus der Traubensilberkerze ergaben eine Reduktion der Hitzewallungen, die vierte Studie wies keinen Effekt auf Hitzewallungen nach, jedoch auf die Intensität des Schwitzens; in der fünften war das Verum dem Placebo nicht überlegen. In einer Phase-II-Studie reduzierten sich unter Einnahme von Leinsamenschrot die Hitzewallungen, eine placebokontrollierte Folgestudie ergab jedoch keinen signifikanten Unterschied zur Kontrolle. Ebenso wurden in einer unkontrollierten Kohortenstudie unter homöopathischer Behandlung positive Effekte auf die klimakterischen Beschwerden der behandelten Patientinnen erreicht, während zwei nachfolgende RCT zu einem Nullergebnis führten. Demgegenüber ergab eine Metaanalyse für die Verum-Akupunktur eine signifikante Überlegenheit gegenüber Sham-Akupunktur. Auch mit einem komplexen Entspannungstraining mit Yoga, Meditation und Atemübungen ließen sich Hitzewallungen im Vergleich zur Kontrolle statistisch signifikant reduzieren. Zwei kleine unkontrollierte Pilotstudien zeigten nach Stellatumblockade einen deutlichen Rückgang von Anzahl und Schwere der Hitzewallungen. ABSTRACT: Many breast cancer patients suffer from the side-effects of endocrine therapy. Climacteric complaints with hot flashes, night sweats, sexual dysfunction, anxiety, depression and musculoskeletal pain lead to a worsening of therapy adherence in many cases. Concurrent therapy with selective serotonin reuptake inhibitors (SSRIs), gabapentin or clonidine have been shown to be effective in several randomized clinical trials (RCT) but many patients refuse to use these medications because they are afraid of additional side-effects. Complementary therapies are popular but the quality and quantity of clinical research in this field has only increased relatively recently. The three RCTs with isolated soy isoflavones did not show superiority compared to placebo. In three out of five clinical studies with black cohosh a reduction of hot flashes was shown, in the fourth study there was no effect on hot flashes but sweating was reduced in the treatment group, in the fifth study there was no difference between verum and placebo. In a phase II study a daily intake of 40 g bruised flax seed reduced hot flashes by 50%. Nevertheless, a placebo-controlled study could not confirm these data. Homeopathic treatment was helpful in an observational study but positive effects were not reproducible in two following RCTs. In a recent meta-analysis of acupuncture in treating hot flashes in breast cancer patients, verum acupuncture was significantly more effective than sham acupuncture. Also a complex 8 week treatment group with yoga, meditation and breathing exercises reduced hot flashes in breast cancer patients and the results of two small pilot studies suggest that stellate ganglion block might also decrease the number and severity of hot flashes.
    09/2011; 26(5). DOI:10.1007/s12312-011-0678-3
Show more